Finance

Lists
NATCOPHARM:NSE
Natco Pharma Ltd
790,50 INR
-0,62%
(-4,90) 1D
9 ოქტ, 15:30:02 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for NATCOPHARM...
Open
795,40 INR
High
801,70 INR
Low
787,45 INR
Mkt. cap
141,56 მლრ.
Avg. vol.
440,88 ათ.
Volume
233,11 ათ.
Dividend
0,56%
Quarterly dividend
1,12 INR
Ex-dividend date
20 აგვ. 2026
P/E ratio
12,47
52-wk high
1 216,89 INR
52-wk low
785,65 INR
EPS
63,37 INR
Shares outstanding
182,26 მლნ.
No. of employees
4 ათ.
Open
795,40 INR
High
801,70 INR
Low
787,45 INR
Mkt. cap
141,56 მლრ.
Avg. vol.
440,88 ათ.
Volume
233,11 ათ.
Dividend
0,56%
Quarterly dividend
1,12 INR
Ex-dividend date
20 აგვ. 2026
P/E ratio
12,47
52-wk high
1 216,89 INR
52-wk low
785,65 INR
EPS
63,37 INR
Shares outstanding
182,26 მლნ.
No. of employees
4 ათ.
News stories
From web sources and news partners
Profile
Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations, active pharmaceutical ingredients and agrochemical products. It is a major producer of branded oncology medicines cardiology, diabetology and other pharma specialty drugs at affordable prices. Wikipedia
About Natco Pharma Ltd
CEOრაჯივ ნანაპანენი
Employees4,43 ათ.
Founded1981
HeadquartersBanjara Hills, ტელანგანა, ინდოეთი
SectorPharmaceutical industry
Last report
14 აგვ. 2026
Fiscal period
Q1 2027
11,53 INR / 8,86 INR
+30,06%beat
Revenue / Est. (INR)
7,35 მლრდ. / 7,96 მლრდ.
-7,66%miss
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
13,63 მლრდ.
6,47 მლრდ.
7,43 მლრდ.
7,35 მლრდ.
Cost of goods sold
1,70 მლრდ.
1,33 მლრდ.
1,99 მლრდ.
1,48 მლრდ.
Cost of revenue
1,70 მლრდ.
1,33 მლრდ.
1,99 მლრდ.
1,48 მლრდ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,00 მლრდ.
1,59 მლრდ.
1,63 მლრდ.
1,79 მლრდ.
Operating expense
6,66 მლრდ.
4,02 მლრდ.
4,38 მლრდ.
4,48 მლრდ.
Total operating expenses
8,36 მლრდ.
5,35 მლრდ.
6,37 მლრდ.
5,96 მლრდ.
Operating income
5,27 მლრდ.
1,12 მლრდ.
1,06 მლრდ.
1,39 მლრდ.
Other non operating income
1,00 მლრდ.
581,00 მლნ.
-2,11 მლრდ.
592,00 მლნ.
EBT including unusual items
6,14 მლრდ.
1,72 მლრდ.
1,80 მლრდ.
2,70 მლრდ.
EBT excluding unusual items
6,14 მლრდ.
1,72 მლრდ.
2,02 მლრდ.
2,70 მლრდ.
Income tax expense
958,00 მლნ.
207,00 მლნ.
-892,00 მლნ.
634,00 მლნ.
Effective tax rate
15,61%
12,03%
-49,61%
23,49%
Other operating expenses
4,14 მლრდ.
1,96 მლრდ.
2,23 მლრდ.
2,22 მლრდ.
Net income
5,18 მლრდ.
1,52 მლრდ.
2,68 მლრდ.
2,06 მლრდ.
Net profit margin
38,03%
23,40%
36,08%
28,09%
Earnings per share
28,94
8,46
14,96
11,53
Interest and investment income
-
-
2,33 მლრდ.
-
Interest expense
-131,00 მლნ.
-95,00 მლნ.
-
-130,00 მლნ.
Net interest expenses
-131,00 მლნ.
-95,00 მლნ.
2,33 მლრდ.
-130,00 მლნ.
Depreciation and amortization charges
524,00 მლნ.
462,00 მლნ.
504,00 მლნ.
471,00 მლნ.
EBITDA
5,82 მლრდ.
1,57 მლრდ.
1,55 მლრდ.
1,91 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google აპები